The nonrandomized, single‐arm, single‐center Phase II CAP 03 study of apatinib in combination with camrelizumab (PD‐1 inhibitor) and temozolomide (NCT04397770) enrolled a total of 50 patients with advanced acral melanoma in the first‐line treatment [448]. Here, PDCD1 is linked to acral lentiginous melanoma.